Hikita Katsuya, Honda Masashi, Shimizu Ryutaro, Teraoka Shogo, Kawamoto Bunya, Yumioka Tetsuya, Tsounapi Panagiota, Iwamoto Hideto, Morizane Shuichi, Takenaka Atsushi
Division of Urology, Department of Surgery, Tottori University Faculty of Medicine, Tottori, Japan.
Cancer Diagn Progn. 2021 Nov 3;1(5):451-457. doi: 10.21873/cdp.10060. eCollection 2021 Nov-Dec.
The efficacy of docetaxel and carboplatin with oral estramustine was evaluated in patients with castration-resistant prostate cancer.
Patients were treated with intravenous docetaxel at 30 mg/m2 on days 1, 8, 15, and 22 of a 28-day cycle. Intravenous carboplatin (area under the curve, 6 mg/ml/min) was administered on day 1. Patients received oral estramustine at 626.8 mg/day throughout the treatment protocol. Patients were evaluated for response, with treatment continued until cancer progression or onset of severe adverse events.
Twenty patients with castration-resistant prostate cancer were treated for a median of 3.5 cycles. Prostate-specific antigen decreased by more than 30% in 18 patients, including 14 patients with a decrease of more than 50%. Median overall survival was 11 months, prostate-specific antigen progression-free survival was 6.5 months, and radiographic progression-free survival was 7 months.
Docetaxel and carboplatin with oral estramustine shows efficacy against castration-resistant prostate cancer.
评估多西他赛、卡铂联合口服雌莫司汀治疗去势抵抗性前列腺癌患者的疗效。
患者在28天周期的第1、8、15和22天接受30mg/m²的静脉多西他赛治疗。第1天给予静脉卡铂（曲线下面积，6mg/ml/分钟）。患者在整个治疗方案中每天口服626.8mg雌莫司汀。评估患者的反应，治疗持续至癌症进展或出现严重不良事件。
20例去势抵抗性前列腺癌患者接受了中位3.5个周期的治疗。18例患者的前列腺特异性抗原下降超过30%，其中14例患者下降超过50%。中位总生存期为11个月，前列腺特异性抗原无进展生存期为6.5个月，影像学无进展生存期为7个月。
多西他赛、卡铂联合口服雌莫司汀对去势抵抗性前列腺癌显示出疗效。
